3,138 Results

Cardiovascular comorbidity in rheumatic diseases.

Patients with rheumatoid arthritis (RA) and other inflammatory joint diseases (IJDs) have an increased risk of premature death compared with the general population, mainly because of the risk of cardiovascular disease, which is...

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.

Determining biosimilarity involves a comprehensive exercise with a focus on determining the comparability of the molecular characteristics and preclinical profile of the biosimilar and reference product, such that there is less need for...

Psoriatic arthritis: Epidemiology, diagnosis, and treatment.

Our understanding of psoriatic arthritis has evolved as new knowledge of the disease has emerged. However, the exact prevalence of psoriatic arthritis is unknown, and its pathogenesis has not been fully elucidated.

Global prevalence of ankylosing spondylitis.

Objectives: For effective health care provision, knowledge of disease prevalence is paramount. There has been no systematic endeavour to establish continent-based AS estimates, however, prevalence is thought to vary by country and...

Comorbidities in inflammatory bowel disease: a call for action.

Inflammatory bowel disease (IBD) is a chronic systemic inflammatory condition. Previously, the focus has been on extraintestinal manifestations of IBD, including arthritis, psoriasis, and uveitis.

The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.

Objective: Inflammatory bowel disease [IBD] entails a high economic burden to society. We aimed to estimate the current and future impact of the introduction of biosimilars for infliximab on IBD-related health care costs.

The Role of Biosimilars in Inflammatory Bowel Disease.

Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available.

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

The coming wave of patent expiries of first generation commercialized biotherapeutical drugs has seen the global market open its doors to close copies of these products. These near perfect substitutes, which are termed as "biosimilars"...

The biosimilar approval process: how different is it?

Biosimilars are biotherapeutic products with similar efficacy, safety, and quality to a licensed bio-originator. Biosimilars include monoclonal antibodies, soluble receptors, growth factors, and hormones.

Era of biosimilars in rheumatology: reshaping the healthcare environment.

Compared with the original approved biological drug on which it is based, a biosimilar has highly similar physicochemical characteristics and biological activity, as well as equivalent efficacy and no clinically meaningful differences...

Load more